Printer Friendly

Clinical Klebsiella pneumoniae Isolate with Three Carbapenem Resistance Genes Associated with Urology Procedures--King County, Washington, 2018.

On December 31, 2018, Public Health--Seattle & King County (PHSKC) was notified by the Antibiotic Resistance Laboratory Network regarding a carbapenem-resistant Klebsiella pneumoniae (CR-Kp) isolate cultured from the urinary tract in a man aged 65 years. The specimen was collected on December 17, 2018. It tested positive for carbapenemase activity by the modified carbapenem inactivation method and positive for genes encoding the carbapenemases New Delhi metallo-beta-lactamase, Verona integron-encoded metallo-beta-lactamase, and OXA-48--type beta-lactamase, by polymerase chain reaction. Antimicrobial susceptibility testing by broth microdilution showed resistance to 15 antibiotics tested * but low minimum inhibitory concentrations (MIC) to colistin (MIC [less than or equal to] 0.25) and tigecycline (MIC = 1). CDC recommends a public health response when organisms with emerging forms of antibiotic resistance, such as the metallo-beta-lactamases this isolate harbored, are identified ([dagger]) because such organisms are often difficult to treat and have the potential to spread rapidly in health care settings (1).

Since September 2017, the patient had been treated at a local outpatient urology clinic (facility A) in King County, Washington, for lower urinary tract symptoms that included urinary retention and benign prostatic hyperplasia. Procedures at facility A before identification of CR-Kp included cystoscopy, urinary catheter placement, and computed tomography scan of the urinary tract. On November 1,2018, he underwent outpatient urodynamic studies at a hospital in Punjab, India (facility B), where urinary and rectal catheters were placed for cystometric and pressure flow studies; he did not undergo cystoscopy and was not hospitalized. Lower urinary tract symptoms persisted, and upon the patient's return to the United States, a urinalysis at facility A on December 17 revealed an elevated white blood cell count and presence of leukocyte esterase, which led to the urine culture that identified CR-Kp. The patient's chronic symptoms and signs remained unchanged, and he was not treated at the time of CR-Kp identification per standard guidelines (2,3). Urinary and rectal specimens to screen for carbapenem-resistant Enterobacteriaceae (CRE) were collected on February 18, 2019; both specimens were negative by polymerase chain reaction (rectal swab) and culture (urine).

After identification of CR-Kp, education was provided to the patient and his family about preventing spread of the organism in the home and sharing this medical history with future medical providers (4). Facility A flagged the patient record for contact precautions. Staff members from PHSKC and the Washington Department of Health inspected facility A to ensure infection control procedures were in place. CRE identifications are notifiable conditions in Washington (2), and no other patients with matching CR-Kp strains have been identified from facility A. PHSKC recommended that facility A maintain contact precautions for the patient, pending results of rescreening for CRE 6 months after the positive culture.

This case highlights two important considerations for preventing antibiotic resistance spread. First, when responding to emerging antibiotic resistance, health departments should consider on-site standardized infection control assessments^ in outpatient settings associated with an elevated risk for transmission, such as those that perform procedures involving the digestive tract, urogenital tract, and wounds. Second, providers should obtain thorough travel histories for any medical care received outside of the United States during the previous 6 months (5). Patients who had overnight hospital stays or underwent outpatient medical procedures abroad should be considered at risk for colonization or infection with CRE. To quickly identify and prevent CRE transmission, providers should consider CRE screening for patients who have undergone medical procedures abroad and who will be hospitalized or undergo invasive procedures in the United States. Carbapenem-resistant organisms from patients with this history should be tested for carbapenemases. Carbapenemase testing for CRE and carbapenem-resistant Pseudomonas aeruginosa and screening for carbapenemases in suspected isolates may be requested by state health departments through the Antibiotic Resistance Laboratory Network. ([paragraph])


Laboratory staff members from the Clinical and Environmental Laboratory Branch, CDC.

Corresponding author: Kirsten Vannice,

[1] Epidemic Intelligence Service, CDC; [2] Public Health--Seattle & King County, Seattle, Washington; [3] Washington State Department of Health, [4] Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, CDC.

All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.


(1.) Woodworth KR, Walters MS, Weiner LM, et al. Vital signs: containment of novel multidrug-resistant organisms and resistance mechanisms--United States, 2006-2017. MMWR Morb Mortal Wkly Rep 2018;67:396-401.

(2.) Washington State Department of Health. Carbapenem-resistant Enterobacteriaceae (CRE) reporting and other carbapenem-resistant organisms. Tumwater, WA: Washington State Department of Health; 2018.

(3.) Nicolle LE, Gupta K, Bradley SF, et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. Clin Infect Dis 2019;68:1611-5. Epub March 21, 2019.

(4.) CDC. Carbapenem-resistant Enterobacteriaceae (CRE) infection: patient FAQs. Atlanta, GA: US Department of Health and Human Services, CDC; 2015.

(5.) CDC. Facility guidance for control of carbapenem-resistant Enterobacteriaceae (CRE): November 2015 update. Atlanta, GA: US Department of Health and Human Services, CDC; 2015.

Kirsten Vannice, PhD [1,2]; Eileen Benoliel [2]; Kelly Kauber, MPH [3]; Claire Brostrom-Smith, MSN [2]; Patricia Montgomery, MPH [3]; Meagan Kay, DVM [2]; Maroya Walters, PhD [4]; Michael Tran [3]; Marisa D'Angeli, MD [3]; Jeff Duchin, MD [2]

* amikacin, aztreonam, cefepime, ciprofloxacin, doripenem, doxycycline, ertapenem, gentamicin, imipenem, levofloxacin, meropenem, minocycline, piperacillin/tazobactam, tobramycin, and trimetho/sulfa.



COPYRIGHT 2019 U.S. Government Printing Office
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Notes from the Field
Author:Vannice, Kirsten; Benoliel, Eileen; Kauber, Kelly; Brostrom-Smith, Claire; Montgomery, Patricia; Kay
Publication:Morbidity and Mortality Weekly Report
Geographic Code:9INDI
Date:Aug 2, 2019
Previous Article:Candida auris in a U.S. Patient with Carbapenemase-Producing Organisms and Recent Hospitalization in Kenya.
Next Article:Vol. 68, No. 17.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |